Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

Benzinga Newsdesk www.benzinga.com Positive 82.1%

Neg 0% Neu 0% Pos 82.1%

Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $150.